Statistical properties of Continuous Composite Outcomes: Implications for clinical trial design

被引:2
|
作者
Troy, Jesse D. [1 ,2 ]
Simmons, Ryan A. [2 ]
机构
[1] Duke Univ, Marcus Ctr Cellular Cures, Sch Med, Durham, NC 27706 USA
[2] Duke Univ, Dept Biostat & Bioinformat, Sch Med, 424 Erwin Rd Suite,1102 Hock Plaza Box 2721, Durham, NC 27710 USA
关键词
Clinical trials; Treatment outcome; Statistics;
D O I
10.1016/j.conctc.2020.100655
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Statistical efficiency can be gained in clinical trials by using composites of time-to-event outcomes when the individual component outcomes have low event rates. However, the utility of continuous composite outcome measures is not as clear. Efficiency can be either gained or lost by using a continuous composite outcome measure depending on several factors, including the strength of correlation between the component outcomes and the size of the treatment effect on each component. In this article we review these concepts from the standpoint of planning a new trial. Statistical properties of composites formed from normally distributed continuous outcomes are discussed. An example dataset is used to demonstrate concepts and complete mathematical details are provided. Finally, a conceptual model for clinical trial design with continuous composites is proposed that could be used as a guide to evaluate the utility of a continuous composite outcome in a future trial based on existing knowledge in the therapeutic area.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Immunotherapy: clinical trials - optimal trial and clinical outcomes
    Bousquet, Philippe Jean
    Demoly, Pascal
    Passalacqua, Giovanni
    Canonica, G. Walter
    Bousquet, Jean
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 7 (06) : 561 - 566
  • [22] Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of oncology trials
    Perlmutter, A. S.
    Tran, V. -T.
    Dechartres, A.
    Ravaud, P.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 688 - 695
  • [23] Statistical considerations in the design, conduct and analyses of antiemetic clinical trials - An emerging consensus
    Morrow, GR
    Ballatori, E
    Groshen, S
    Olver, I
    SUPPORTIVE CARE IN CANCER, 1998, 6 (03) : 261 - 265
  • [24] Statistical considerations in the design, conduct and analyses of antiemetic clinical trials An emerging consensus
    G. R. Morrow
    Enzo Ballatori
    Susan Groshen
    Ian Olver
    Supportive Care in Cancer, 1998, 6 : 261 - 265
  • [25] Clinical Trial Design in Neuroendocrine Tumors
    Halperin, Daniel M.
    Yao, James C.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (01) : 209 - +
  • [26] Outcomes of a Cancer Clinical Trial Matching Service
    Ted Gansler
    Man Jin
    Joseph Bauer
    Katie Dahlquist
    Larissa Tis
    Katherine Sharpe
    Robert Comis
    Kimberly Naples
    James Kepner
    Journal of Cancer Education, 2012, 27 : 11 - 20
  • [27] An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast Cancer
    Erik Bloomquist
    Susan Jin
    Jiaxi Zhou
    Shenghui Tang
    Rajeshwari Sridhara
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 861 - 869
  • [28] Outcomes of a Cancer Clinical Trial Matching Service
    Gansler, Ted
    Jin, Man
    Bauer, Joseph
    Dahlquist, Katie
    Tis, Larissa
    Sharpe, Katherine
    Comis, Robert
    Naples, Kimberly
    Kepner, James
    JOURNAL OF CANCER EDUCATION, 2012, 27 (01) : 11 - 20
  • [29] Central statistical monitoring in clinical trial management: A scoping review
    Fronc, Maciej
    Jakubczyk, Michal
    Love, Sharon B.
    Talbot, Susan
    Rolfe, Timothy
    CLINICAL TRIALS, 2025,
  • [30] An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast Cancer
    Bloomquist, Erik
    Jin, Susan
    Zhou, Jiaxi
    Tang, Shenghui
    Sridhara, Rajeshwari
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (04) : 861 - 869